Corbus Pharmaceuticals
CRBP
34 hedge funds and large institutions have $4.54M invested in Corbus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
21,300% more call options, than puts
Call options by funds: $214K | Put options by funds: $1K
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
26% more funds holding
Funds holding: 27 → 34 (+7)
0.2% more ownership
Funds ownership: 16.81% → 17.01% (+0.2%)
9% less capital invested
Capital invested by funds: $5.01M → $4.54M (-$466K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$112K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.39K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.17K |
| 4 |
Morgan Stanley
New York
|
+$4.43K |
| 5 |
Citigroup
New York
|
+$3.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$67.3K |
| 2 |
JP Morgan Chase
New York
|
-$6.24K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.62K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$3.12K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1.24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Studio Investment Management
Chicago,
Illinois
| $55 | – | – | – |
|
|
NA
27
NewEdge Advisors
New Orleans,
Louisiana
| $48 | – | – | – |
|
|
SA
28
Scarborough Advisors
Annapolis,
Maryland
| $36 | +$32 | +6 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $24 | +$21 | +4 | New |
|
|
IA
30
IFP Advisors
Tampa,
Florida
| $18 | – | – | – |
|
31
Comerica Bank
Dallas,
Texas
| $6 | – | – | – |
|
|
SSB
32
Sandy Spring Bank
Olney,
Maryland
| $6 | – | – | – |
|
33
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$16 | +3 | New |
|
|
KFP
34
Keener Financial Planning
Keller,
Texas
| – | +$32 | +6 | New |
|
CRBP Hedge Fund Activity: Q4 2023 in Review
34 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2023, worth a combined $4.54M — down 9.3% from $5.01M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CRBP positions and 1 closed out — a net gain of 7 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $112K. The largest seller was Dimensional Fund Advisors, cutting an estimated $67.3K.
- 34 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2023, up from 27 in Q3 2023.
- Funds reported $4.54M of Corbus Pharmaceuticals stock for Q4 2023, down 9.3% quarter-over-quarter.
- 8 funds opened new Corbus Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +7 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2023 was Royal Bank of Canada, an estimated $112K added.
- The largest Corbus Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $67.3K sold.
Based on aggregated 13F filings for Q4 2023.